The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer
Par un écrivain mystérieux
Description
The Lancet Oncology, January 2024, Volume 25, Issue 1, Pages 1-146
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
Perioperative dose-dense methotrexate, vinblastine, doxorubicin
The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme
Frontiers TTCC-2019-02: real-world evidence of first-line
Randomized Phase III Trial of Concurrent Accelerated Radiation
Gemcitabine–cisplatin versus MVAC chemotherapy for urothelial
Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic
Expert Insight on Optimal Treatment Selection for Patients With
Frontiers A Multicenter Phase II Trial of Docetaxel, Cisplatin
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil
ESMO 2021: GETUG/AFU VESPER V05 Phase III Trial of Dose Dense
depuis
par adulte (le prix varie selon la taille du groupe)